Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen Sells 3,331 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.00, for a total value of $23,317.00. Following the completion of the sale, the chief executive officer now owns 74,123 shares in the company, valued at approximately $518,861. This trade represents a 4.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Atara Biotherapeutics Price Performance

ATRA stock opened at $6.90 on Friday. The stock has a market capitalization of $39.74 million, a price-to-earnings ratio of -0.27 and a beta of 0.46. The business’s fifty day moving average price is $9.85 and its two-hundred day moving average price is $9.71. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.40 and a fifty-two week high of $20.81.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($3.82) by $2.63. The firm had revenue of $32.75 million for the quarter, compared to the consensus estimate of $20.58 million. Research analysts expect that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group dropped their price target on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Institutional Trading of Atara Biotherapeutics

Large investors have recently modified their holdings of the stock. FMR LLC boosted its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Vestal Point Capital LP boosted its stake in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares in the last quarter. State Street Corp boosted its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 7,680 shares in the last quarter. Geode Capital Management LLC boosted its stake in Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares in the last quarter. Finally, Staley Capital Advisers Inc. boosted its stake in Atara Biotherapeutics by 25.0% in the fourth quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 10,000 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.